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Dr Thoralf Sundt (Rochester, Minn). I have a few questions for
you. First, I congratulate you on doing such a multicenter study,
and those who have attempted to do even a registry like this can
appreciate the complexity of it. This is a complex condition, and
if we are going to make progress, we do need to do these kinds
of studies, but it is a lot of work just to collect the information. I
tip my hat to you on that, and really with a remarkably low mortal-
ity rate.
I have a fairly technical question. In our institution, it is almost
impossible anymore to get the interventional radiologists to do an
adequate pulmonary angiogram, and they have themselves begged
us to use high-resolution CT scanning, and we have basically aban-
doned pulmonary arteriography in favor of CT scanning with re-
constructions. I wonder if the same is true in Europe.
Dr Mayer. I have to disagree. I believe that for an adequate
evaluation of operability, pulmonary angiography is still the stan-
dard technique, and I do believe that CT angiography, even high-
resolution CT, 256-row CT, is not an adequate procedure, because
most of the radiologists believe they have to show clot in the
pulmonary arteries, but we are not speaking about clot, we are
speaking about 1-mm obstructions in segmental arteries. So it
might be possible to use it in central disease, but it is not possible
to use it in peripheral distal disease.
Dr Sundt. The second question relates to the learning curve.
You have a large number of patients but also a large number of cen-
ters, and you showed us the relationship betweenmortality rate and
center experience, but what about surgeon experience? Certainly
for me this has been a difficult operation with a steep learning
curve, and I still believe I am on that learning curve. I wonder if
you have any information about the relationship on a surgeon-
by-surgeon basis related to the learning curve, not just for mortal-
ity rate but residual PVR and, for that matter, the judgment about
operability.
Dr Mayer. We do not have the data for the whole registry. We
have the data for single centers. But notably, in the registry, you
had a look at the article, we could demonstrate that the centers
with low volume had a better postoperative PVR reduction com-
pared with the centers with high volume, probably because of
the intense selection of proximal candidates. So in centers
with high volume, many distal endarterectomies are performed
with some grade of microvascular disease, and therefore the
decrease of PVR might not be as hard compared with proximal
disease.
We know that the learning curve is intense, not only for the
surgeon but also for the people who make the evaluation and for
postoperative care, but we don’t have the data for the whole
registry.rdiovascular Surgery c Volume 141, Number 3 709
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DDr Sundt. My last question really is a political one. We heard
yesterday about regionalization of lobectomy in Canada and in
this same vein in terms of the learning curve. Do you think a rela-
tively uncommon procedure like this should be done in only a few
centers, in a center of excellence type model, or what is your view
on that?
Dr Mayer. I think this operation should be performed only in
excellent centers, and the situation in Europe is very different.
For example, in England and France, there is only 1 center. Every
patient with CTEPH who undergoes an operation is referred to
Paris or Cambridge. In other countries there are centers with
high volume, but there are also several centers doing 2 or 3 cases
per year. This is not a good idea, because 1 death of 3 cases is 33%.
DrMichael Madani (San Diego, Calif). As you know, we have
been performing pulmonary endarterectomies for more than 2 de-
cades now, and we have done more than 2500 of these cases. It is
clear that this condition is still severely underdiagnosed and a large
number of patients are being denied surgery, even after the diagno-
sis is made.What is really disturbing, in the United States, and per-
haps more in Europe, is a wider application of the newer
vasodilator and antiproliferative agents preventing or delaying sur-
gical referrals. Although I agree that there may be eventually a role
for these agents in patients with residual pulmonary hypertension
after PEA or in preoperative patients when there is a severe mis-
match between clot burden and degree of pulmonary hypertension,
the bottom line is that this is a mechanical condition and requires
a mechanical solution.
The issue of operability is really the key issue of my discussion.
We believe that if there is evidence of thromboembolic disease,
surgery should be performed. This is particularly important, as
you just mentioned, with the CT scan, as well as the angiogram,
because most preoperative studies tend to underestimate the true
clot burden.We have found that more than 90% of patients referred
to us who are deemed inoperable at other centers or because they
have so-called distal disease really experience significant hemody-
namic improvement after full endarterectomy. The mortality rate
in the last 500 in our series is less than 3%. I would like to know710 The Journal of Thoracic and Cardiovascular Surghow this registry will address this issue of inoperability among
the 17 centers, including those with such low volumes?
Dr Mayer. The problem is that it was a noninterventional reg-
istry, so we took the data from the different centers. I completely
agree that the evaluation of operability is also a factor of learning
curve, and it is the same in our center, that many patients are sent
deemed inoperable, and they are clearly operable because some-
times they even have poor diagnostics. I do believe that every pa-
tient with diagnosed CTEPH should be referred to a surgical center
without delay and without medical treatment. There are no data
supporting preoperative medical treatment.
Dr Madani. I have one more question for you. I noticed in the
article that you used a PVR of 1500 as the cutoff for operability and
that in your data you had patients with higher PVRs. If you could
clarify why you are using a PVR of 1500 as a cutoff?
DrMayer.No, we are not using a PVR of 1500.Wewere asking
the surgeons why they did not perform PEA, and we were
asking for reasons, and one reason was very high PVR. Patients
with high PVRs, as seen in the numbers, were not excluded from
surgery.
Dr R. Duane Davis (Durham, NC). The incidence of acute lung
injury or ischemia-reperfusion or whatever you want to call it
seemed to be dramatically decreasing over the time. Is this a learn-
ing effect or the application of essentially the reperfusion strate-
gies that we use in lung transplant? Have you standardized that
across the centers or are you using this platform to improve process
across the centers in terms of an educational standpoint?
DrMayer. That is what wewant to do. Wewant to use this plat-
form for future studies, because there are no studies on periopera-
tive treatment at the moment. And it is true, over the last 20 years,
reperfusion lung injury has been significantly decreased and is not
a clinically significant problem anymore. We don’t know the exact
reasons for that, but we believe that a faster operation and better
postoperative care with regard to hemodynamics (eg, keeping
the cardiac index low) are good measures to reduce pulmonary re-
perfusion edema, but it is a multifactorial development. But it has
decreased significantly, you are right.ery c March 2011
